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Despite recent advances, the majority of patients with multiple myeloma (MM) relapse or progress. For a subset of patients, salvage high-dose chemotherapy and autologous hematopoietic stem cell transplantation (auto-HCT) can yield a meaningful duration of remission [1] [2] [3] and may improve time to progression in comparison with traditional salvage chemotherapy. 4 Recent data have suggested that combination of lenalidomide with traditional cytotoxic chemotherapy is safe and may result in synergistic antimyeloma effects, even in patients previously treated with lenalidomide. 5, 6 We therefore hypothesized that lenalidomide could be safely combined with high-dose melphalan in the salvage auto-HCT setting. We further postulated that increasing the dose of lenalidomide would not add unacceptable toxicity, as cytopenias would be ameliorated by the planned autologous rescue. Thus, this setting would provide us the opportunity to study higher doses of lenalidomide, which, to date, have not been examined in MM.
We conducted a phase I/II study to determine the safety and efficacy of lenalidomide in combination with high-dose melphalan (NCT01079936). Patients between the ages of 18 and 80 years who had relapsed or had progressive MM 7 were eligible. The study was approved by the Institutional Review Board. Patients received 7 days of lenalidomide (between 25 and 100 mg orally daily for the 7 days) on days − 8 and − 2. High-dose melphalan (total of 200/ m 2 ) was administered as 100 mg/m 2 intravenously on days − 3 and − 2. Rescue autologous stem cell graft was on day 0. Standard supportive care measures were provided per departmental protocol. There were four doses of lenalidomide in the dose escalation phase: 25, 50, 75 and 100 mg. The first 12 patients were treated at these dose levels (three patients per level) and safety was assessed at each level. The dose for each subsequent patient was chosen in a sequentially adaptive manner to optimize the trade-off between toxicity and efficacy. 8 Dose-limiting toxicity was defined as regimen-related death, graft failure, grade 3 or 4 atrial fibrillation, grade 4 deep venous thrombosis or pulmonary embolism before day 30 after auto-HCT. Efficacy was defined as being alive in complete response (CR) 7 at day 90 (±30 days) after auto-HCT. Multiparameter flow cytometry (CD19, CD20, CD38, CD45, CD56, CD81, CD117, κ or λ light chains and CD138) further identified patients in CR with no evidence of minimal residual disease (multiparameter flow cytometry-CR).
Overall survival (OS) and progression-free survival (PFS) were estimated by the method of Kaplan and Meier. The log-rank test was used to assess differences in OS or PFS between subgroups. Exact tests for association between categorical variables were carried out using the Fisher's exact and Fisher-Freeman-Halton test. 9,10 Bayesian binary regression 11 was used to assess possible multivariate relationships between the probability of day 90 CR and patient covariates. Bayesian survival time regression 12 was used to assess the relationship between OS, PFS and patient covariates. The four lenalidomide dose levels were standardized by dividing the mean dose, represented as 0.40, 0.80, 1.20 and 1.60. To interpret the fitted Bayesian regression models, a posterior probability Prob(β40|Data) for the coefficient β of a covariate in the model of either 40.95 or o 0.05 was considered 'significant', and a value either 40.99 or o 0.01 was considered 'highly significant'. Values in the ranges 0.90-0.95 or 0.05-0.10 were considered 'moderately significant'.
From March 2010 to April 2013, 57 patients were enrolled. Patient characteristics are summarized in Table 1 . Twenty-two (39%) patients were lenalidomide-refractory, 30 (53%) bortezomib-refractory and 13 (23%) refractory to both. Patient characteristics did not differ significantly between the lenalidomide dose levels, with the exception that patients in dose level 1 were more likely to have responsive disease going into the auto-HCT.
Dose-limiting toxicities were not seen at any of the four dose levels. After safely escalating to 100 mg, patients were adaptively randomized among the four lenalidomide dose levels (Table 1) . Grade 3-4 non-hematologic toxicity was seen in 40 (70%) patients, with no significant differences between the four dose levels (Supplementary Table 1 ). Two patients died of nonrelapse causes (viral infection 1, cardiac failure 1) for a treatment-related mortality of 3%. Median time to both neutrophil and platelet engraftment was 11 days. Thus far, only one patient has developed a second primary malignancy (squamous cell cancer of the skin).
By day 90 after auto-HCT, 8 (14%) patients had achieved a CR (including the 3 patients in CR before auto-HCT), 25 (44%) a CR or very good partial response (VGPR) and 42 (74%) a CR, VGPR or partial response (PR), with no significant differences in response rates among the four lenalidomide dose levels (Supplementary Table 1 ). By day 180, 12 patients (21%) had achieved a CR. Of these (Figures 1a and b) . By log-rank test, there were no significant differences in either PFS or OS between the doses of lenalidomide (P = 0.27 and 0.15 respectively; Figures 1c and d) .
Two-year PFS and OS probabilities were 48% (95% confidence interval: 32-62%) and 72% (95% confidence interval: 56-84%), respectively. There was no significant difference in median PFS (13 months) or OS (not yet reached) for patients undergoing a second auto-HCT in comparison with patients undergoing first auto-HCT as a salvage treatment after progression (P = 0.47 and 0.85, respectively). For the 38 patients with previous exposure to lenalidomide, there was an improvement in PFS (but not OS) for the 26 patients who were sensitive to lenalidomide versus the 12 lenalidomide-refractory patients (23.2 versus 5.3 months respectively, P = 0.01). Of note, 36 (63%) patients went on to receive postauto-HCT maintenance therapy (lenalidomide: 32; bortezomib: 2; pomalidomide: 2).
On multivariate analysis, high-risk cytogenetics, percent plasma cell infiltration of bone marrow (%PCs) and the number of prior lines of treatment were each significantly associated with a lower probability of reaching CR by day 90 (Prob(β40) of 0.0114, 0.0430 and 0.0110, respectively). For PFS, higher lenalidomide dose level and longer time from diagnosis were significantly beneficial, whereas higher lactate dehydrogenase was moderately significantly harmful, even after accounting for high-risk cytogenetics and %PCs (Prob(β40) of 0.9770, 0.9909, 0.0936, respectively). Factors that independently affected OS included higher dose level (Prob(β40) = 0.9466) and longer time from initial diagnosis to auto-HCT (Prob(β40) = 0.9568), both of which were beneficial. In contrast, high-risk cytogenetics and higher lactate dehydrogenase both adversely affected OS (Prob (β40) = 0.0507).
Previous studies have suggested that a salvage auto-HCT, as a first or second transplant after relapse or progression is relatively well tolerated. 2, 13 In the current trial, we studied escalating doses of lenalidomide, ranging from 25 to 100 mg for 7 days, and determined that higher doses of lenalidomide could be safely combined with myeloablative chemotherapy with only 3% treatment-related mortality. This was a high-risk population with 450% refractory to lenalidomide or bortezomib and a median of three lines of prior therapy. Importantly, there were no significant delays in engraftment or increase in thromboembolic events, and only one patient developed a second primary malignancy. This suggests that the platform of autologous stem cell rescue may, in fact, be the ideal venue for delivering high doses of immunomodulatory agents.
The CR rate (14% at day 90) and overall response rate (74% at day 90) are comparable to those seen with other salvage regimens. 14 The median PFS of 23.7 represents an improvement from our prior data in this population, 2 and is comparable to other salvage studies 15 and a randomized study of auto-HCT versus salvage chemotherapy for relapsed MM patients. 4 However, we acknowledge that this patient population was heterogeneous and thus further study is warranted in a more defined patient population. Although the small patient number places some limitation on interpretation, there is a suggestion that this treatment could still be considered for patients who may have not previously been referred for auto-HCT but who now have relapsed disease.
Our adaptive study design ultimately determined that the highest doses of lenalidomide (75 and 100 mg) were equivalent to achieve a balance between tolerability and efficacy. Owing to relatively small patient numbers, a longer follow-up time may further differentiate the true clinical effect of the dose escalation and the impact of post-auto-HCT maintenance therapy, which 63% of patients received. Unfortunately (although not surprisingly), poor-risk cytogenetics independently predicted for poorer OS, reminding us of the continued need for innovative treatment options for these patients.
In conclusion, combination of high-dose melphalan with highdose lenalidomide appears to be a well tolerated and safe preparative regimen in the setting of salvage auto-HCT. As novel agents, maintenance regimens and immunotherapies emerge, it is conceivable that they too may be combined with this auto-HCT platform to offer the relapsed patient yet another chance at a durable response.
